Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

REMEVi vs Trillium Meds

REMEVi
Graded #70

Higher grade

vs+4.099999999999994
Trillium Meds
Graded #124

Lower grade

The verdict

REMEVi takes it — 73.5/100 to 69.4/100.

REMEVi grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. REMEVi is the first bilingual (English and Spanish) GLP-1 telehealth clinic — care delivered by clinicians trained in both languages, never auto-translated.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueTrillium Meds +13
57
70
Dose & formulationREMEVi +19
83
64
Clinical oversightREMEVi +2
86
84
Labs & monitoringTrillium Meds +20
55
75
FulfillmentREMEVi +18
97
79
Contract termsREMEVi +49
69
20
REMEVi · left barTrillium Meds · right bar

The numbers

MetricREMEViTrillium Meds
WeighScore73.5/10069.4/100
GradeCC
Scorecard rank#70#124
Semaglutide$219/mo$119/mo (3-month plan, compounded)
Tirzepatide$319/mo$199/mo (3-month plan, compounded)
CoverageAll 50 statesAll 50 states
Brand-name accessCompounded onlyCompounded only
Oral / sublingualYesInjection only
REMEVi

Graded #70 · C

Strengths

  • A genuinely flat rate: 'the same price at every dose', stated as such, with no dose upcharge and no introductory rate to step off
  • Longer terms are published openly rather than used as a teaser — semaglutide falls to $189 on 12 weeks and $149 on 52
  • A daily oral semaglutide tablet is offered alongside the injection
  • Available in all 50 states and DC, with no minimum commitment and no cancellation fee

Where it loses points

  • The flat rate is the highest entry price of the top-scoring programmes here; the cheaper $149 figure needs a full year
  • No FDA-approved brand-name pathway — the Wegovy and Ozempic pages are comparison content, not products
  • Compounded semaglutide and tirzepatide are not FDA-approved finished products
Trillium Meds

Graded #124 · C

Strengths

  • LegitScript certified with an active seal; serves all 50 states plus Puerto Rico with no geographic restrictions
  • All-inclusive pricing covers medication, provider consultation, and shipping with no hidden fees or add-ons
  • Two pharmacy options (BPI Labs with B6, ProRx) and three plan structures: 1-month, 3-month fixed, or 3-month titrated
  • Small owner-operated; founder personally handles customer support outside business hours for direct, responsive service
  • Klarna and Affirm financing available; pause anytime with no long-term commitment required

Where it loses points

  • No labs, coaching, or clinical monitoring included — telehealth Rx and pharmacy fulfillment only
  • Small single-operator platform may limit capacity and support consistency as patient volume grows
  • Compounded medications are not FDA-approved; newer platform with limited long-term public track record
  • Tirzepatide from $199/mo (3-mo plan) is mid-market; sema from $119/mo competitive but not lowest available
  • No live video consult disclosed; async intake-form-based provider review by external licensed provider network

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard